Cost effectiveness and biotechnology.
D000900:Anti-Bacterial Agents / Q000191:economics; D001315:Australia; D001709:Biotechnology / Q000191:economics*; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000191:economics; D016179:Granulocyte Colony-Stimulating Factor / Q000191:economics; D006526:Hepatitis C / Q000517:prevention & control; D006801:Humans; D007328:Insulin / Q000191:economics; D011663:Pulmonary Surfactants / Q000191:economics; D011994:Recombinant Proteins / Q000191:economics; D013678:Technology, Pharmaceutical / Q000191:economics; D010959:Tissue Plasminogen Activator / Q000191:economics; D014761:Viral Hepatitis Vaccines / Q000191:economics
D000900:Anti-Bacterial Agents; D007328:Insulin; D011663:Pulmonary Surfactants; D011994:Recombinant Proteins; D014761:Viral Hepatitis Vaccines; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D010959:Tissue Plasminogen Activator